Support The Moscow Times!

Pharmstandard Sales Up 84%

Drug maker Pharmstandard said Thursday its third-quarter sales soared 84 percent, year-on-year, boosted by an early state tender for anti-cancer drugs.

Sales totaled 14.7 billion rubles, versus 8 billion rubles in the same period last year, the company said in a statement.

It said sales of Johnson & Johnson's anti-cancer drug Velcade totaled 4.8 billion rubles, accounting for one-third of total revenue, after the government shifted its tender to the third quarter from the fourth quarter.

As a result, total sales of third-party products soared 308 percent to stand at 8.1 billion rubles, while sales of the company's own drugs were up 8.3 percent to 6.2 billion rubles.

(Reuters)

Related articles:

Read more

Independent journalism isn’t dead. You can help keep it alive.

As the only remaining independent, English-language news source reporting from Russia, The Moscow Times plays a critical role in connecting Russia to the world.

Editorial decisions are made entirely by journalists in our newsroom, who adhere to the highest ethical standards. We fearlessly cover issues that are often considered off-limits or taboo in Russia, from domestic violence and LGBT issues to the climate crisis and a secretive nuclear blast that exposed unknowing doctors to radiation.

As we approach the holiday season, please consider making a one-time donation — or better still a recurring donation — to The Moscow Times to help us continue producing vital, high-quality journalism about the world’s largest country.